Quoin Pharmaceuticals (NASDAQ:QNRX) Issues Earnings Results, Misses Expectations By $8.38 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) announced its quarterly earnings results on Thursday. The company reported ($14.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.42) by ($8.38), Zacks reports.

Quoin Pharmaceuticals Trading Down 15.3%

QNRX opened at $6.41 on Friday. Quoin Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $41.80. The firm has a market cap of $5.38 million, a price-to-earnings ratio of -0.19 and a beta of 1.60. The company has a fifty day simple moving average of $8.45 and a 200 day simple moving average of $11.10.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Quoin Pharmaceuticals

Several large investors have recently modified their holdings of the business. ADAR1 Capital Management LLC acquired a new position in shares of Quoin Pharmaceuticals in the fourth quarter worth about $840,000. Boothbay Fund Management LLC acquired a new stake in Quoin Pharmaceuticals during the 4th quarter valued at approximately $863,000. SummitTX Capital L.P. purchased a new stake in Quoin Pharmaceuticals during the 4th quarter worth approximately $935,000. Millennium Management LLC acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at approximately $1,080,000. Finally, Ikarian Capital LLC acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at approximately $3,052,000. 8.63% of the stock is currently owned by institutional investors and hedge funds.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.